The 7investing Podcast

The biggest bottleneck in the AI infrastructure boom isn't chips — it's power. Simon Erickson and Heather Horton deep dive into two 7Investing watchlist additions built for exactly this moment: Bloom Energy (NYSE:BE) and Lumentum (NASDAQ:LITE). Bloom's modular solid oxide fuel cells deliver on-demand power with no combustion emissions, a $22 billion backlog, and a brand new deal with Oracle (NYSE:ORCL) that sent the stock up 23% in a single day — doubling their existing partnership to 2.8 gigawatts of AI data center power production.Then Simon breaks down Lumentum's laser transceiver technology that converts electrical signals into optical signals for faster, more efficient data transfer inside hyperscale data centers. NVIDIA (NASDAQ:NVDA) was so convinced they signed a multi-year strategic alliance AND invested $2 billion directly into the company. With Jensen Huang projecting $4 trillion a year spent on AI data centers by 2030, both of these picks-and-shovels plays could be sitting at major inflection points.Whether you're investing in AI infrastructure stocks, clean energy stocks, or looking for the next under-the-radar growth opportunity beyond Nvidia, this episode covers two compelling watchlist names worth researching today.

Simon Erickson is back with three major investing trends that every growth investor needs on their radar in 2026. First up: weight loss drugs are bigger than ever, with oral GLP-1 pills from Novo Nordisk and Eli Lilly now winning broad insurance coverage and slashing out-of-pocket costs — potentially tripling the total addressable market to $190 billion by 2035. Then Simon breaks down the picks-and-shovels plays powering the AI data center buildout — including co-packaged optics, on-demand fuel cell energy, and quantum computing — and makes the case for why Bloom Energy may be his top pick in the space right now.Finally, the episode covers what could be the largest IPO in history: SpaceX is reportedly targeting a $2 trillion valuation and a $75 billion raise as soon as this summer — and the implications for the entire space economy are massive. From orbital data centers to Starlink's satellite internet dominance and the Starship launch vehicle, Simon breaks down what investors need to know before SpaceX goes public. Don't miss it — subscribe and visit 7investing.com for full recommendations and watch list access.Past episodes mentioned:GLP-1 Feud: https://youtu.be/CazBaRRT3HQData Centers in Space: https://youtube.com/live/Qmk84KLaX0Y?feature=shareStocks & Companies MentionedPublicly Traded:Novo Nordisk (NYSE:NVO)Eli Lilly (NYSE:LLY)Viking Therapeutics (NASDAQ:VKTX)Hims & Hers Health (NYSE:HIMS)Broadcom (NASDAQ:AVGO)Lumentum (NASDAQ:LITE)Bloom Energy (NYSE:BE)IonQ (NYSE:IONQ)Rocket Lab (NASDAQ:RKLB)MDA Space (TSX:MDA)Micron Technology (NASDAQ:MU)Zeta Global (NYSE:ZETA)NuScale Power (NYSE:SMR)NVIDIA (NASDAQ:NVDA)Alphabet / Google (NASDAQ:GOOGL)Microsoft (NASDAQ:MSFT)Meta Platforms (NASDAQ:META)Watch List Mentions (7Investing):Vail Resorts (NYSE:MTN)Sphere Entertainment (NYSE:SPHR)Ferrari (NYSE:RACE)IonQ (NYSE:IONQ) (also listed above)Private / Pre-IPO:SpaceX (private — IPO expected as soon as summer 2026)xAI (acquired by SpaceX, February 2026)Inflection (newly public quantum computing company — ticker not confirmed in transcript)Anthropic (private)Character.ai (private)Insurance / Healthcare Referenced:BlueCross BlueShield (not publicly traded)UnitedHealthcare / UnitedHealth Group (NYSE:UNH)Aetna / CVS Health (NYSE:CVS)#GLP1Stocks #WeightLossDrugs #OzempicStocks #SpaceXIPO #AIDataCenters #BloomEnergy #QuantumComputing #GrowthInvesting #StockMarket #EnergyStocks #SpaceStocks #Lumentum #Broadcom #NovoNordisk #EliLilly #InvestingIn2026 #TechStocks #PicksAndShovels #7investing #SimonErickson⚠️ This is not investing advice. Please do your own research before making any investment decisions.

In Part 3 of our MIT Tech Review Breakthrough Technologies 2026 series, Simon Erickson goes deep on the three most investable opportunities from the list's two top trends: Hyperscale AI Data Centers and Next Generation Nuclear. This episode features detailed breakdowns of Broadcom (NASDAQ:AVGO), Lumentum (NASDAQ:LITE), and NuScale Power (NYSE:SMR) — covering their business models, revenue growth, competitive advantages, and why they could be among the biggest winners of the AI infrastructure buildout.From Broadcom's $64B revenue empire and custom ASIC chip design powering hyperscale data centers, to Lumentum's explosive 65% revenue growth as NVIDIA's key optical transceiver partner, to NuScale's small modular reactor (SMR) technology and a potential $120–$180B contract with the Tennessee Valley Authority — this episode covers picks-and-shovels investing at its finest.Whether you're focused on AI infrastructure stocks, semiconductor stocks, clean energy stocks, or nuclear power investing, this is a must-watch for long-term growth investors. Subscribe and catch the full three-part series at 7investing.com.

Every year, MIT Technology Review publishes its list of the 10 most important emerging technologies — and every year, Simon Erickson breaks it down through an investor's lens. In this episode, Simon and Heather review MIT's breakthrough technology lists from 2023, 2024, and 2025 to see what's already become reality, then preview the 2026 list live from the MIT Tech Review website. From weight loss drugs and AI-powered search to small language models, next-gen nuclear, and generative coding — which technologies are actually investable right now, and which are still 3–5 years out? Simon walks through the MIT framework alongside the Gartner Hype Cycle and Boston Consulting Group's value creation index to help investors separate the signal from the noise.Whether you're tracking AI companions, sodium-ion batteries, robotaxis, CRISPR gene editing, or hyperscale data centers, this episode gives you the big-picture context to start positioning early in the technologies shaping our future.

The feud between Novo Nordisk (NYSE:NVO) and Hims & Hers (NYSE:HIMS) has been one of the most dramatic storylines in biotech investing — and it just took a major new turn. Simon Erickson breaks down the four-year saga: from Wegovy's launch and the FDA shortage list, to compounded Semaglutide flooding the market at a fraction of the cost, to patent infringement lawsuits, and finally to the new distribution agreement signed March 9, 2026.We cover the explosive growth potential of GLP-1 weight loss drugs, why the global weight loss drug market could hit $200 billion — double the size of the diabetes market — and what the new Wegovy oral pill means for both companies and investors. We also examine how Eli Lilly (NYSE:LLY) fits into the competitive picture with Zepbound and why its U.S.-based advantage has translated into stronger investor sentiment compared to Novo.Simon shares his investor takeaways: Novo's pricing power is under pressure, the IP battle is far from over, and new CEO Mike Doustdar appears to be taking a harder line on patent enforcement. Meanwhile, Hims & Hers emerges from this feud with greater clarity on what it can and can't sell — and the patent infringement overhang on its stock has been lifted.STOCKS MENTIONED:Novo Nordisk (NYSE:NVO)Hims & Hers (NYSE:HIMS)Eli Lilly (NYSE:LLY)#NovoNordisk #nvo #HimsAndHers #hims #GLP1 #Semaglutide #Wegovy #WeightLossDrugs #Zepbound #EliLilly #InvestingNews #PharmaceuticalStocks #BiotechInvesting #StockMarket #GLP1Stocks #CompoundingSemaglutide #WeightLoss #7investing #Simonerickson

Apple (NASDAQ:AAPL) just dropped a bombshell product lineup — including the all-new MacBook Neo at just $600, the iPhone 17E, and the MacBook Air M5 — and they're doing it while raising gross margins. How is that possible in an inflationary, tariff-heavy environment? In this episode, Simon Erickson breaks down Apple's bold pricing strategy, its asset-light business model, and why this could be a major long-term win for investors.We dig into Apple's record-breaking Q1 results: $143.8B in revenue (up 16% YoY), an all-time high gross margin of 48.2%, and $54B in operating cash flow — including $24.7B in share buybacks. We also explore how Apple's reliance on Taiwan Semiconductor (NYSE:TSM) and Broadcom (NASDAQ:AVGO) for chip manufacturing lets it avoid the massive CapEx spending that rivals like Amazon (NASDAQ:AMZN), Alphabet (NASDAQ:GOOGL), Microsoft (NASDAQ:MSFT), and Meta (NASDAQ:META) are racing to deploy.Plus, a preview of our upcoming Friday show: the Novo Nordisk (NYSE:NVO) vs. Hims & Hers (NYSE:HIMS) feud over GLP-1 weight loss drugs — and a future special episode on quantum computing.Don't miss out on our free investing newsletter with show recaps delivered straight to your inbox: 7investing.com/newsletter#Apple #AAPL #MacBookNeo #iPhone17E #MacBookAirM5 #StockMarket #InvestingNews #TechStocks #AppleInvestor #Tariffs #Inflation #GrossMargin #ShareBuybacks #TaiwanSemiconductor #Broadcom #GLP1 #NovoNordisk #HimsAndHers #QuantumComputing #7investing #SimonErickson

Simon Erickson of 7investing breaks down two high-potential watchlist stocks: Micron Technology (NASDAQ:MU) — a memory giant riding the AI boom with explosive margin expansion — and Infleqtion (NYSE:INFQ), a newly public quantum computing company using groundbreaking neutral atom technology. Micron's high bandwidth memory (HBM) is completely sold out through 2026, with gross margins expanding 16 percentage points year-over-year on $13.6B in quarterly revenue. This is one of the most compelling AI infrastructure plays in the semiconductor space right now.Infleqtion just hit public markets via SPAC in February 2026 and is already partnered with NVIDIA (NASDAQ:NVDA) through a CUDA integration called Qlink. With quantum computing threatening RSA encryption and unlocking solutions classical computers can't touch, government contracts, defense spending, and research grants are flooding the space — justifying premium valuations for early-stage leaders.

What a month it has been for our 7investing show!Throughout all of February, we focused on the semiconductor industry - looking for the investment opportunities who were best-poised to benefit from AI's endless demand for computing. We searched far and wide for those top stock ideas, and we featured some incredible guests to share their insights on the show all month.That included: 1) Feb 1: "The Eyes of AI"Emmet Savage and I looked into the new world of "Physical AI" and how it was using solid-state LiDAR to see all of its surroundings. Our stock of focus was Ouster $OUST.https://youtube.com/live/yYpByizVWc02) Feb 9: "The Future of the Chip Industry"Robert Quinn and I discussed Elon's TeraFab idea, space-based datacenters, and why the AI "bubble" is actually more of an AI "inflection point". Our stock of focus was Tesla $TSLA.https://youtube.com/live/Qmk84KLaX0Y3) Feb 16: "Why Infrastructure is the Real Winner in the Age of AI"John Rotonti and I discussed "SaaS-pocalypse" and why several vendors were hidden winners in the $3 trillion AI infrastructure spending through 2030. Our stocks of focus were Amphenol $APH and Trane Technologies $TT.https://youtube.com/live/zFTcaGY3rkM4) Feb 18: "NVIDIA vs AMD: The $1 Trillion AI Chip War Explained"Nick Rossolillo and I described the ambitious forecasts recently issued by chipmakers and the role of newcomers with creative new designs. Our stocks of focus were NVIDIA $NVDA and $AMD. https://youtube.com/live/_p0vhUR2JNY5) Feb 27: "From Fiber Optics Bust to AI Optics Boom: The $700B Optics Opportunity" Eric Bleeker and I discussed how co-packaged optics and advanced packaging could be game-changers for chip efficiency. Our stocks of focus were Applied Optoelectronics $AAOI and Lumentum $LITE. https://youtube.com/live/Paw4f6ay3AgA HUGE THANK YOU to all of our guests in February!We had some great conversations, answered some fun audience questions, and empowered investors to take a closer look at this red-hot chip sector.On today's March 2 show, I'll share the key takeaways from each of these shows mentioned above and then discuss the one semiconductor stock I ultimately selected as my official recommendation for March.

February 27, 2026: Co-Packaged OpticsGenerative AI is getting very demanding.It's become extremely power-hungry, and that's pushing the physical limits of what today's highest-performing chips are even capable of.One potential solution is co-packaged optics, which involves integrating fiber-optic transmitters directly into the chip. It's a great way to avoid much of the heat and signal degradation that traditionally comes from moving data across inefficient copper wires.Overall, that improves computing performance and uses less power. Which is a big win for this entire sector!But there are also significant costs associated with this new advanced packaging technology. Will the hyperscalers be willing to foot the bill, as the pace of their data center buildouts now approaches light speed?On Friday's show, I was joined by 24/7 Wall Street's Eric Bleeker to discuss the opportunity for co-packaged optics.We described why Lumentum has doubled in price during just the past two months and why Applied Optoelectronics is another stock that should be on your investing radar.⚠️ Not financial advice. Do your own research. These stocks have run significantly—understand the risks before investing.#optics #semiconductors #AI #datacenter #NVIDIA #AppliedOptoelectronics #Lumentum #copackagedoptics #AIinfrastructure #chipstocks #investing #stockmarket #7investing #247WallStreet #EricBleeker #advancedpackaging #hyperscalers #Amazon #Google #AIboom #techstocks #stockpicks

Feb 18, 2026: What's Next for AI AcceleratorsAMD's CEO Lisa Su thinks the market for cutting-edge AI chips will be worth $1 trillion annually by 2030 and NVIDIA's CEO Jensen Huang (who happens to be Lisa's cousin once-removed) believes AI infrastructure spend will total $4 trillion during the next five years.If those forecasts are even directionally correct, both AMD and NVIDIA will still have quite an extended growth runway in this red hot semiconductor sector.But are these admittedly self-serving forecasts actually realistic?Or is AI hardware likely to become commoditized and lower-priced during that timeframe?And are there other competitors who might also pose a challenge in this two-horse race?On Wednesday's show, I was joined by Chip Stock Investor founder Nick Rossolillo to describe what lies ahead for both NVIDIA and AMD.We also discussed why Apple is spending significantly on CapEx less than its other Big Tech peers, whether Moore's Law is actually dead, and the role of newcomers like Cerebras Systems and IonQ.#NVIDIA #AMD #semiconductors #AIchips #JensenHuang #LisaSu #chipstocks #datacenter #investing #Broadcom #Apple #TSMC #Cerebras #quantumcomputing #7investing #chipstockinvestor #techinvesting #AIinfrastructure #hyperscalers #GPUvsCPU #waferschale #FormulaOne #poleposition #techanalysis #stockmarket2026

Feb 16, 2026: Why Infrastructure is the Real Winner in the Age of AIWarren Buffett is widely credited with characterizing competitive advantages as moats that companies will aggressively build and will vigorously defend to protect themselves from attacks by others.The software industry has been a popular sector for investors in recent years due to its outsized growth rates and its ability to quickly iterate.Yet the barriers to entry are low here, and it's been difficult for software companies to build sustainable moats.That's perhaps one of the key reasons for the recent "SaaS-pocalypse", where many software stocks have sold off due to the emerging threat of AI and technological disruption.So where do we go from here? Are software stocks with lower prices now a compelling buying opportunity? Or are these falling knives with even more downside risk ahead?On Monday's livestream show, Bastion Fiduciary portfolio manager John Rotonti and I describe the status quo of the software industry. But we also discuss how infrastructure providers are emerging as the real winners in the age of AI.Power, cooling, networking, and other supporting functions are supply-constrained and are doing their best to meet the $3 trillion of AI infrastructure spending that will take place within the next five years. We discuss the turnaround taking place in manufacturing and why Amphenol, TE Connectivity, and Trane Technologies could be lucrative investment opportunities.Timestamps:00:00 – Welcome & Mardi Gras check-in02:30 – The SaaS reckoning: low moats, high competition08:00 – Valuations then vs. now (52x PE → 20x)12:00 – The stock-based compensation problem15:00 – Is it finally time to invest in SaaS?20:00 – Constellation Software: the acquisition machine28:00 – Nvidia & the AI infrastructure buildout38:00 – Hardware + software integration as a moat40:00 – Why Alphabet is the widest-moat AI company43:00 – Power, liquid cooling & the data center arms race47:00 – Labor shortages & re-industrialization50:00 – Audience Q&ALearn more about long-term investing at 7investing.com — get your first 7 days free at 7investing.com/subscribe#7investing #AIStocks #SaaS #Nvidia #Alphabet #JohnRotonti #StockMarket #Investing #AIInfrastructure #IndustrialStocks #ConstellationSoftware #LongTermInvesting

February 13, 2026: AI in Drug DiscoveryIt costs $2.5 billion and up to 10 years of effort to successfully bring a new drug to market.That's an extremely high hurdle to succeed!It's no wonder why the high costs of FDA trials & the elevated rates of failure often result in small-cap drug developers declaring bankruptcy. Biotechnology is one of the stock market's riskiest sectors to invest in.But what if there was a way to change that?What if we could use technology to alleviate some of the biotech industry's deepest and most systemic risks?AI doesn't necessarily produce better drugs. Though it might be able to reduce drug development costs and timelines significantly.And if it did, that would be a game-changer for the entire industry.On today's show, my special guest Manisha Samy and I will discuss how AI-native infrastructure could vastly improve the return profiles of early-stage biotech companies.Our stock of focus will be Recursion Pharmaceuticals (Nasdaq: RXRX) who's creatively using AI to guide several programs in its development pipeline.

Feb 9, 2026: The Future of the Chip Industry1) Elon Musk wants Tesla to bypass Taiwan Semi and to build his own massive "TeraFab" facilities that would supply 20% of the world's chips.2) Datacenters that are launched into Low Earth Orbit would operate more efficiently with lower temperatures, zero-gravity, and with abundant solar power.3) Meta Platforms' new 5 gigawatt Hyperion AI lab will require more power than the current output of America's largest nuclear power plant.These aren't just science fiction ideas, nor are they purely academic discussions.These are actual projects on the table, which would cost hundreds of billions of dollars and years of dedicated effort to complete.And their technological, commercial, and geopolitical implications would be felt everywhere across the world.I recently spoke with Robert Quinn about the future of the semiconductor industry.Robert has spent three decades advising companies, investors, and institutions on how to design and operate fabs and then to optimize their yields.On our show, we discuss Elon's latest ambitions, whether "the AI Bubble" is actually "an inflection point of demand" and several of the important bottlenecks the industry is facing.We also describe investing opportunities, including chip designer NVIDIA, equipment provider ASML, and quantum innovator IonQ.

7investing CEO Simon Erickson and My Wall Street CEO and Prophet founder Emmett Savage as they explore Computer Modelling Group (TSE: GMG) (OTCMKTS: CMDXF) - a hidden gem in the oil & gas software sector that most investors are completely ignoring.Why "special situations" investing can uncover multi-bagger opportunitiesHow Computer Modeling Group provides essential reservoir simulation software to energy giants like ShellWhy CMG's captive customer base and efficient business model make it attractive despite hitting all-time lowsThe potential catalyst on the horizon that could unlock significant valueEmmett's contrarian optimism for 2026 and where to find value in today's marketThis is the third installment in our special situations series, following previous discussions on Ouster (solid-state lidar) and Vertical Aerospace (eVTOL).Computer Modelling Group Trading Information:Toronto Stock Exchange: CMGUS Ticker: CMDXF

Happy Groundhog Day! Punxsutawney Phil saw his shadow (6 more weeks of winter ☃️), but consumer discretionary stocks are about to heat up!What is Consumer Discretionary?NOT consumer staples (milk, eggs, cereal)The "wants" not "needs" - retailers, restaurants, automakers, home improvementAmazon, Tesla, Home Depot, Lowe's, McDonald's, Chipotle, StarbucksHighly cyclical - outperforms in good times, underperforms in downturnsWhy the Last 5 Years Were Rough:COVID impact on restaurants, brick-and-mortar retail2022: Fed raised rates 7 times (crushed consumer spending)2025: International tariffs pushed up pricesNike, Lululemon: Multiple quarters of negative compsMedian 5-year return: ~9.8% (vs typical 11-12%)Why 2026 Could Be Different:ChatGPT Ads Launch - 1 billion users, new ad format for retailersLower customer acquisition costs - More platforms = cheaper conversionsEasier year-over-year comps - 2025 was terrible, 2026 looks betterInternational brands too cheap - Crocs at 6x free cash flow?!CEO turnarounds - Major brands hiring new leadershipSupply chains stabilizing - Post-tariff efficiency gainsThe ChatGPT Game-Changer:1 billion users (50M paying $200/month for Pro)New ad format: Embedded product suggestions in promptsExample: "Mexican dinner ideas" → Hot sauce ad placementSimilar to Google's playbook: Free product → Monetize with adsRetailers get NEW low-cost acquisition channelStock Opportunities Discussed:- Lovable brands selling cheap: Nike, Lululemon, Crocs- Restaurant plays: Starbucks, Domino's, Chipotle, Cava Group- Software crossover: DraftKings, Duolingo (100M+ users each)- Tesla: Robotaxi progress, new Elon pay package- Adobe: "Dead" due to AI? Still 40% FCF margins, strong retention- The Trade Desk: Collapsed in 2025, cyclical downturn ≠ dead company

The future isn't just AI that thinks—it's AI that SEES and INTERACTS with the physical world.Simon Erickson chats with Emmett Savage (MyWallStreet & Prophet founder) to break down Ouster (OUST)—the company making "seeing eyes for AI" through breakthrough solid-state LIDAR technology. No moving parts. Pure semiconductor engineering. And it's already deployed in over 100,000 sensors.This isn't a paved road—it's early and risky. But we might be looking at one of the ultimate building blocks of seeing machines.Stocks Discussed:Ouster (OUST) - Featured stockVertical Aerospace - Previous EVTOL discussionServ Robotics - Delivery robotsTesla, Apple - Tier-1 customersiRobot, Mobileye, InvenSense - Historical comparisonsNext Episode Monday (Feb 2): Simon reveals the space where his NEXT 7investing recommendation operates (Groundhog Day special!)Next Episode Wednesday (Feb 4): Emmett returns with a THIRD off-radar stock pick

January 26, 2026: Air Taxis and Vertical AerospaceKeep your eyes on the skies, because electric vertical takeoff and landing aircraft are about to be taking off.Not quite an airplane and not quite a helicopter, an eVTOL is perhaps best described as a piloted drone that carry passengers. They ascend straight up during takeoff, are quieter than a refrigerator, give off zero emissions, and can reach top speeds of 200 miles per hour.eVTOLs are a unique new form of transportation that could reduce traffic congestion in densely-populated areas and are gaining regulatory clearances in both the US and abroad. Several companies are already conducting pilot programs that have been partially-funded by airlines and automakers.On Monday's show, MyWallSt's founder Emmet Savage and I discuss how this new industry is reaching a higher altitude.Our stock of focus was Vertical Aerospace (NYSE: EVTL) a fascinating innovator who's also much less inexpensive than its other eVTOL peers.⚠️ Not financial advice. Do your own research before investing.#evtol #watchlist #stockpicks #dividends #chipstocks #marketing #7investing #investing2026 #techinvesting

Welcome to 7investing's Watch List! Today we're diving deep into TWO stocks that aren't official recommendations but are on the 7investing radar: Broadcom (a massive dividend-paying chip giant) and Zeta Global (an AI-powered marketing disruptor)

On January 1, 2026, Warren Buffett officially stepped down as CEO of Berkshire Hathaway and handed the reins to his longtime lieutenant Greg Abel.Buffett had been CEO of $BRKB for the past 60 years, and Berkshire's stock price had increased 5.5 million percent during his six-decade tenure.What's next for one of the world's greatest publicly-traded companies of all time?On today's @7investing Live show, my special guest Auri Hughes @Auri_Invest and I will discuss how massive leadership transitions can impact a company and how investors should evaluate them when deciding to buy or sell a stock.Our stock of focus today will be Constellation Software $CNSWF, whose CEO Mark Leonard similarly stepped down after three decades at the helm.

Note: We experienced technical difficulties during the live stream, but Steve Symington's insights were so good we wanted to keep this. An edited version will be available soon. AI has taken the investing world by storm in recent years, and NVIDIA's high-performance computing chips have made it the market darling of this space.Yet we're still in only “the third inning” when it comes to investing in AI. Forward-thinking companies are harnessing the power of large language models and machine learning inference to improve their own operations. Those doing it well are gaining significant market share on their slower-moving competitors.Lemonade is a perfect example, who is using AI to improve the insurance industry.In today's episode, former 7investing advisor Steve Symington joins the show to describe how investors should size up the companies who are embracing AI. He also takes a detailed look at Lemonade, suggesting the juice is worth the squeeze for this refreshing innovator.Key Insight: The best AI investments aren't always the chip makers—they're the companies built from the ground up with AI as their foundation, disrupting industries where incumbents are too slow to adapt.⚠️ Technical difficulties during the live stream, but the insights are worth the watch.

Welcome to the inaugural guest episode of 7investing Live for 2026!Simon Erickson sits down with Spencer Randall, founder and CEO of CryptoEQ, to explore the collision of equities and cryptocurrencies—and what it means for your portfolio.What We Cover:- NASDAQ's Bold Move - Why the Nasdaq exchange is seeking SEC approval to tokenize equities, which would enable 24/5 global trading on blockchain- The "Everything App" Race - How Coinbase, Robinhood, and SoFi are competing to become America's WeChat- The Mullet Strategy - Business in front, party in the back! How Coinbase is offering 40-50% lower interest rates through decentralized finance- Regulatory Winds Shifting - The Genius Act, Clarity Act, and why the regulatory environment is now favoring crypto adoption- Neo-Banking Revolution - Why crypto-native financial services are disrupting traditional banking- Coinbase Deep Dive (COIN) - Stock focus on the leading US crypto exchange and its diversifying revenue streams- Beginner vs Expert Exchanges - Which crypto platforms Spencer recommends for different experience levelsFeatured Companies:Coinbase (COIN)Robinhood (HOOD)NASDAQ (NDAQ)Crypto Exchanges: Kraken, Gemini, StripeGuest: Spencer Randall has been following crypto daily for 8 years and co-founded CryptoEQ in 2020 to provide institutional-grade research on digital assets.

Welcome to the 2026 kickoff of 7investing Live! In this special episode, Simon Erickson breaks down three game-changing insights for individual investors:- The Real Advantage You Have Over Wall Street - No style box limitations, no herd mentality, and the freedom to invest anywhere. Learn why institutions are actually at a disadvantage.- Why the Newsletter Industry Has Been Doing It Wrong - With millions of opinions flooding the market, how do you cut through the noise? We're embracing collaboration over competition.- What's Coming in 2026 - Get a sneak peek at our upcoming guests including cryptocurrency experts, AI analysts, dividend specialists, and biotech researchers. We're building a network of insights, not just one perspective.Upcoming January 2026 Guests:Spencer Randall (CryptoEQ) - Cryptocurrencies & CoinbaseEmmett Savage (MyWallStreet) - AI-powered stock discoveryJames Early (Curia Financial) - Dividend & value investingManika Premsingh - Healthcare & biotech trendsSteve Symington - Artificial intelligence deep dive7investing Live streams every Monday, Wednesday & Friday at 10am ET with interactive Q&A, diverse perspectives, and stocks the herd isn't watching yet.

The 10 Second Takeaway: DraftKings and other online sports betting platforms are losing market share to predictive markets. DraftKings (Nasdaq: DKNG) and FanDuel (owned by Flutter Entertainment (NYSE: FLUT)) have enjoyed more than 80% share for years in America's online sports betting market duopoly.But now they're adjusting to a new player who's recently joined their table.Privately-held Kalshi has a reserved seat to allow gamblers to bet on sporting events. Yet this isn't the same as its larger peers, and its new approach is taking the industry by storm.Kalshi isn't just another online sports book. It is technically an exchange who sells financial products that are tied to the outcomes of sporting events.That legal distinction is important, because Kalshi and other predictive market platforms are regulated by the Commodity Futures Trading Commission at the federal level. That's quite different from online sports betting platforms, who are regulated by each individual state.DraftKings and FanDuel have been lobbying endlessly on a state-by-state basis, trying not only to get their apps legalized but also for them to have consistent tax rates. Even after decades of operations, online sports betting is still only legal in 38 states + the District of Columbia.Yet Kalshi's financial products are available in all 50 states and have quickly sidestepped the traditional book of rules.As expected, the money is flowing to what's more universally available. The NY Times reported that Kalshi facilitated more than $2.5 billion worth of sports contracts in September alone, with the majority being on NFL games.That's a pretty formidable number, especially when considering the total cash handle for all sports betting last year was around $150 billion.There are political ties here as well. Kalshi named Donald Trump Jr as a strategic advisor one week before the president's inauguration, and the Trump Administration further issued tax cuts that are financially advantageous for future contracts as compared to traditional gambling.I don't personally see much of a difference between prediction market financial contracts and online sports bets. They're pretty much identical in function and are placed in exactly the same way within the apps by users.Yet in this highly-regulated industry, Kalshi and its predictven market peers appear to have been given a Trump Card. And that's providing an important edge that is causing it to win big at the expense of others.DraftKings will report its third quarter earnings in early November. I'll grab a front row seat and some popcorn, eager to see how this game will ultimately play out. See all of our coverage on DraftKings at 7investing.com/DKNG

Is Quantum Computing Investable?In a @7investing exclusive interview, I recently spoke with @TiernanRayTech about the status quo of quantum computing.Tiernan has had a front row seat for technology innovation for decades. Quantum is making headlines once again, and he shared insights on what's really going on behind the scenes.Publicly-traded companies like $IONQ Rigetti $RGTI, and D-Wave $QBTS have been making significant commercial progress, often growing their top-line sales at triple-digit rates.But those companies are also priced at an average of 260x forward sales -- which are nosebleed multiples that are putting the "AI bubble" to shame!So is quantum technology ready for the main stage yet? Why would you use it steady of classic computing? And are there any companies here actually worth investing in?Tiernan and I reviewed the challenges quantum faces, the tech roadmaps being pursued, the applications where it makes the most sense, and why quantum could actually be really good for $NVIDIA.We also discussed how investors should approach this space and the potential role of future acquisitions.Thank you Tiernan for sharing your insights with 7investing!https://7investing.com/article/are-we-still-five-more-years-from-quantum-computing-with-special-guest-tiernan-ray/

Lemonade (NYSE: LMND) is a new player who's really adding zest to the insurance industry. Its AI-powered underwriting enables it to write new policies much more efficiently than its less-tech-savvy traditional competitors.And in addition to its agent-related costs being a fraction of others, its unique Synthetic Agents marketing approach is providing a very lucrative LTV/CAC of 3X (which is very good).In this 7investing exclusive livestream event, I shared a formal presentation that included insights about Lemonade's fundamental results, key metrics, competitive differentiation, current valuation, and technical trading factors that might make this stock particularly intriguing.It was also an interactive event, with a real-time chat and questions in the Q&A. I enjoyed this refreshing event, where we found out whether Lemonade is worth the squeeze as an investment. Thank you to all who attended live!

The digital advertising industry is, in many ways, a bellwether of the American economy. It's a direct look at how and where companies are acquiring new customers, as well as how things are going in the business world.PubMatic (Nasdaq: PUBM) is one of the digital advertising industry's earliest trailblazers. Founded in 2006, its mission has always been to provide a platform for PUBlishers to autoMATICally monetize their websites, podcasts, and streaming TV channels with programmatic ads. In the future, that might expand to new formats like VR headsets or even self-driving cars. 7investing recently sat down with PubMatic founder & CEO Rajeev Goel to discuss how he sees the digital ad industry evolving. Here's a look at the topics we discussed:1) Industry overview (0:00): Where does digital advertising stand in 2025?2) Competitive advantage (4:45): What are PubMatic's structural sources of competitive advantage, especially compared to your peers?3) The Next Big Thing (13:32) : Header bidding for CTV in 2020, then Connect in 2022, then Activate in 2023. What's your next major growth format?4) Connected TV (18:26) : Streaming ads seem more interactive now. How is CTV evolving?5) Supply Path Optimization (22:32) : SPO is still 55% of total activity yet DBRR fell during Q1. Have the large publishers now fully consolidated their inventory?6) The Trade Desk (26:02): The Trade Desk continues to promote OpenPath and says it will disrupt the industry. How do you believe OpenPath will most likely impact PubMatic?7) The Macro (33:24): Several forecasts are reducing expectations for ad budgets in 2025. What are you seeing on the near-term horizon?8) Capital Allocation (37:46): Just announced a $100m buyback expansion. How are you prioritizing capital allocation to maximize shareholder value?Are you ready to begin investing in your future? Join 7investing today at 7investing.com/subscribe and get your first 7 days absolutely free!

Today's 7investing podcast is all about Rocket Lab!The space economy is hitting an inflection point. And that will be good news for its earliest investors.Eastern European conflicts, standoffs between China and Taiwan, and new commercial interests are creating a trillion-dollar industry in Earth's orbit. And this is much more than just glorified media hype. An unprecedented number of applications is forcing the FCC to streamline its review process, as the number of active satellites is growing incredibly quickly.Rocket Lab (NASDAQ: RKLB) is in the perfect position to benefit. This small-cap, small-launch provider's revenues will skyrocket during the next decade, while also dramatically reducing its costs due to the reusability of its rockets.Its rocket scientist CEO Peter Beck is a New Zealand gem, not afraid to get his hands dirty and don the hard hat to build bigger rockets and serve more demanding customers. Credibility and long-term relationships are vitally important in the launch industry. Rocket Lab is gaining both…at an accelerating pace.The Solar System is the limit for this disruptor. Rocket Lab is a very high risk investment who faces a myriad of challenges, but is also growing quickly in a massive and mostly unexplored new market. It's time to place another bet on the Final Frontier.

Today's 7investing podcast is all about Rocket Lab!The space economy is hitting an inflection point. And that will be good news for its earliest investors.Eastern European conflicts, standoffs between China and Taiwan, and new commercial interests are creating a trillion-dollar industry in Earth's orbit. And this is much more than just glorified media hype. An unprecedented number of applications is forcing the FCC to streamline its review process, as the number of active satellites is growing incredibly quickly.Rocket Lab (NASDAQ: RKLB) is in the perfect position to benefit. This small-cap, small-launch provider's revenues will skyrocket during the next decade, while also dramatically reducing its costs due to the reusability of its rockets.Its rocket scientist CEO Peter Beck is a New Zealand gem, not afraid to get his hands dirty and don the hard hat to build bigger rockets and serve more demanding customers. Credibility and long-term relationships are vitally important in the launch industry. Rocket Lab is gaining both…at an accelerating pace.The Solar System is the limit for this disruptor. Rocket Lab is a very high risk investment who faces a myriad of challenges, but is also growing quickly in a massive and mostly unexplored new market. It's time to place another bet on the Final Frontier.

Three Catalysts that Could Send Crocs' Stock SoaringOriginally recorded: May 9, 2025Some great investment opportunities are sexy tech companies that are growing quickly and everyone is familiar with. But others can be boring shoe companies, who are growing slowly and yet are ridiculously profitable.Crocs (Nasdaq: CROX) is an example of the latter. Stuck between the uncertainties of a recession, slowing consumer spending, and a trade war, CROX is now selling for just 7x its trailing earnings. That's very cheap; a clear sign the market is putting these shares on the bargain rack.But Simon has found three hidden catalysts that he believes could drive the price of this small-cap significantly higher. He discussed them on today's 7investing podcast. This show is sponsored by Prophet. Prophet's AI engine incorporates fundamental and technical analysis to make stock recommendations every month. With an outstanding track record over 16 years, it's the perfect tool for passive investors who want actionable ideas but don't have a lot of time.Through 7investing's exclusive partnership, new members can get a $50 discount and also the first two months free by visiting ⁠https://www.useprophet.com/7investing⁠But hurry: this no-upfront-cost deal is only available until July 7th!

Palantir and Upstart: Soaring Growth but Falling Stock Prices Originally recorded: May 7, 2025Palantir Technologies (Nasdaq: PLTR) and Upstart Holdings (Nasdaq: UPST) are two of the market's hottest stocks. Both are using AI to enhance their intelligent platforms and are seeing their top-line growth accelerate.Yet curiously, even after reporting excellent quarterly results, both stocks are selling off significantly.Are there hidden risks that investors are becoming more worried about? Or have the baked-in expectations simply gotten too high?Simon digs into both companies on today's 7nvesting podcast.As a perfect fit for an episode about AI, this show is sponsored by Prophet. Prophet's AI engine incorporates fundamental and technical analysis to make stock recommendations every month. With an outstanding track record over 16 years, it's the perfect tool for passive investors who want actionable ideas but don't have a lot of time.Through 7investing's exclusive partnership, new members can get a $50 discount and also the first two months free by visiting useprophet.com/7investing. This no-upfront-cost deal is only available until July 7th!

What the heck is going on at Wolfspeed?!Originally recorded: May 6, 2025The WSJ published an article that WOLF is now the most shorted stock in the entire US market. The company's CFO then unexpectedly stepped down.And yet even after what appeared to be the worst-case scenario, recent negotiations have resulted in its stock price doubling within just the past two weeks.I dug into the filings and took a closer look at a Bloomberg terminal with a special situations guru that I called up earlier this week.Here's exactly what's going on with one of the market's most volatile stocks. Are you ready to get started with 7investing, to see all of our active recommendations, our five monthly Best Buys, our buy/hold/sell conviction ratings, and our interactive community forum? If so, your first week is free at: ⁠7investing.com/subscribe

We're bringing back the 7investing podcast!After remaining dormant for a few months, 7investing founder Simon Erickson introduces the new-and-improved show format. That will include:Deeper company-specific insights - including Wolfspeed's financial stability, AMD's leap into the datacenter, Palantir's stock-based compensation, and The Trade Desk's valuation (and that is all just this week!)New guests - including those looking at different sectors of the market such as REITs, crypto, banking, dividends, special situations, and international opportunitiesExclusive offers - new partnerships with other investing newsletters and products with exclusive rates for the 7investing audienceLivestream formats - recorded live and available for guests to join at riverside.fm/studio/7investing-live.I'm excited to get started with our new-and-improved 7investing podcast. See you in the speakers!Are you ready to get started with 7investing, to see all of our active recommendations, our five monthly Best Buys, our buy/hold/sell conviction ratings, and our interactive community forum? If so, your first week is free at:7investing.com/subscribe

Options guru Jeff Fischer discusses with 7investing how options can be used as a complement to stocks to boost the returns of a long-term investment portfolio.When used responsibly, options can be a fantastic way to boost the overall returns of an investment portfolio.But options are also shorter-term in nature and they are more highly-exposed to risks and uncertainties. So how, exactly, should investors be using them responsibly? Jeff Fischer has three decades of investing experience. Between writing content for retail investors, co-founding multiple options newsletters, and even managing a hedge fund, he has a wealth of knowledge about investing strategies to generate long term returns.In our recent conversation on March 7, 2025, Jeff discussed how options can be a long-term investor's best friend for boosting returns -- but they also have a few nuances that shouldn't be ignored.Options are best used as a complement to stocks. Jeff describes why he's often writing puts to generate income when he wants to buy a stock at a particular price and writing calls when he's willing to sell a stock for a certain price.We also discussed how investing in options can be slightly different than investing in stocks. Due to their shorter-term nature, options are more exposed to the behavior of the stock market and are more heavily influenced by its current mood of optimism or pessimism. While technical factors do play a role, options strategies should still be built upon fundamental research and valuation.Jeff then described the tradeoff between an option's intrinsic value and its time value. When selling options, you get paid the premium upfront; and you can later buy it back in the future to close out the contract. Jeff typically looks to close out options positions he has written if they've reached 80% or more of the premium's total value -- meaning there's less than 20% of the initial premium left on the contract.We then discussed the difference between retail and institutional investors. Retail investors have the freedom to invest anywhere they would like, but institutions prefer much more predictability and credibility. When retirement funds are at stake, institutional investors are looking for their fund managers to reliably execute on the strategy they were created to accomplish. In the outro, Jeff offered the sectors and stocks that he most enjoys to invest in. During his 30 year career, he's mostly preferred software companies like Alphabet and Meta Platforms. He also mentioned Airbnb as a most recent opportunity investors might want to consider.To have our investing insights delivered to your Inbox every week, please join our free 7investing newsletter today.

Crocs is a very inexpensive stock right now, which could represent an excellent value investment opportunity. Crocs is a global shoe retailer whose comfortable and inexpensive footwear generates $4 billion in annual sales. Its core Crocs brand is growing 17% internationally and 8% direct-to-consumer. Q3 sales got a boost from "Mini-Crocs" being included in McDonald's $MCD Happy Meals and "Batman Crocs" being sold through a recent partnership with DC Comics (both of which are quite adorable). But its recently-acquired HEYDUDE brand has been struggling. HEYDUDE's sales fell 17% this year, as it's not yet resonating with the younger consumer demographic. Crocs is doubling-down on HEYDUDE's brand by hiring Sydney Sweeney to be the long-term ambassador of its marketing. She's encouraging others to be comfortable in their own shoes, and this feels like a good first step to getting sales back on track. As an investment, Crocs looks very inexpensive. The stock is trading at just 7x earnings and 6.5x free cash flow, but it's generating a 70% return on equity and a 25% return on invested capital. There's a pretty clear disconnect there. Crocs' core business is solid and profitable. Yet the market is pricing it as a fad that's in a permanent decline. If the company's new marketing efforts pay off, this inexpensive stock might be worth snapping your jaws on as one of the stock market's most compelling opportunities. See our complete 7investing coverage on Crocs -- including how well it performs based on the legendary value investor Joel Tillinghast's framework -- at: https://7investing.com/company_name/crocs/…

Taiwan Semiconductor $TSM, the world's largest chipmaking foundry, today just issued the largest CapEx forecast of its company's history.Does this mean the chip industry is finally escaping from its cyclical lows, and is ready for a rebound in 2025? TSMC's 4Q 2024 results showcased a 38% year-over-year increase in revenue and a 57% increase in earnings. Those were good numbers. But there might be even better news on the horizon. Management just approved a 2025 capital budget of between $38 billion and $42 billion. 70% of that is dedicated to "advanced technology production" -- i.e. building new fabs to manufacture the cutting-edge chips demanded by AI. This aggressive CapEx forecast is good news for TSMC and also for the entire semiconductor industry. The company will be spending that 2025 budget on equipment vendors such as $ASML, Applied Materials $AMAT, and Axcelis Technologies $ACLS and also on boatload of supporting functions. Meanwhile, creative innovations are also unlocking new opportunities. Taiwan Semi is transitioning the fundamental architecture of its transistors from FinFET to gate-all-around. It's updating the foundation its entire house is built on; changing the physical design of the smallest building blocks of its circuits to support more efficient and powerful processors. The next few years will be an exciting time for this industry. The semiconductor renaissance looks well-primed to begin a new chapter. See all of our @7investing coverage on $TSMC -- including our current Conviction Rating on the stock -- at:https://7investing.com/company_name/taiwan-semiconductor-manufacturing-company/

Innovation and regulation are quite often at odds. Technology relentlessly marches onward; yet it also needs to safely serve the common good. This is ever so true in banking. While banking may have traditionally been considered to be a rather conservative industry, its innovation curve has steepened significantly as physical banks have gone digital, digital banks have employed AI for lending, and managed accounts are embracing cryptocurrencies. Today's 7investing podcast features two banking experts, Caitlin Long and John Maxfield, who share their perspectives on the industry's innovation and offer their insights on: - How crypto-bank Silvergate managed (amazingly) to survive an 80% run on its deposits after the collapse of FTX. - Why overly-restrictive regulations such as excessive capital requirements and limitations on crypto might be soon to change. - What expectations the industry should have of the incoming SEC Chairman Paul Atkins and how he differs from outgoing chair Gary Gensler. - How 'debanking' is unfairly punishing many of the industry's key innovators In the final outro, 7investing CEO Simon Erickson plays a game of "over or under", to hear Caitlin and John's differing insights on a variety of popular companies and topics. This was truly an epic conversation between two banking Wyomingites! Follow @CaitlinLong_ and @MaxfieldonBanks on X/Twitter for even more of their insights. Disclaimer: 7investing's hosts and guests may have positions in the companies or cryptocurrencies discussed on this podcast. Nothing discussed in this program should be considered professional financial advice. To learn more about 7investing, visit our website at 7investing.com.

It's an exciting time to invest in the banking sector. Newly-elected President Donald Trump has promised to relax regulations on banks, which could boost lending volumes. The Federal Reserve has lowered interest rates twice during the past two months, which could make companies more eager to borrow. In response, several publicly-traded financial services companies including Upstart Holdings (Nasdaq: UPST), Affirm Holdings (Nasdaq: AFRM), and SoFi Technologies (Nasdaq: SOFI) have seen their share prices skyrocket and are generating fantastic gains for their investors. But will this momentum continue? What impact will Trump's administration really have on banking? And what, specifically, should those of us investing in banking be watching for? In today's podcast, 7investing CEO Simon Erickson gets the answers to those questions from banking expert John Maxfield. The two discuss why the macro is favorable for banking, yet also a few cautionary things to watch out for at SoFi. Disclaimer: 7investing and its guests may have active positions in the companies mentioned in this podcast. To see all of 7investing's active recommendations, sign up for a 7-day free trial of our service at 7investing.com/subscribe.

Veeva Systems (NYSE: VEEV) is helping pharmaceutical companies create and sell new drugs more efficiently. It's cloud-based software platforms Veeva CRM and Veeva Vault have become industry-standards; deeply embedded with Big Pharma's largest companies. There's an upcoming catalyst next year, as Veeva's CRM platform will migrate from being hosted by Salesforce to its own infrastructure. That will unlock opportunities for it to develop new software products -- perhaps even beyond life sciences -- to make the pie larger with its largest customers. As interest rates fall, it's likely new VC funding will flow into smaller biotech companies and will unlock a new SMB revenue stream as well. 7investing CEO Simon Erickson describes both of these catalysts, as well as why he believes the stock is undervalued, in today's 7investing podcast. To see all of our official stock recommendations and our monthly Best Buys, get started with 7investing at ⁠7investing.com/subscribe⁠. Your first week of our premium membership is entirely free!

The Dutch lithography juggernaut ASML (Nasdaq: ASML) has been one of the semiconductor industry's best performing stocks of the past decade. Yet its high-flying shares have sold off 33% in the past three months, perhaps due to its underwhelming forward guidance that could indicate slowing demand. ASML has looked to Intel (Nasdaq: INTC) for much of its growth this past year. Intel has been all-in on expanding its foundry group and aggressively placed orders for six of ASML's latest-and-greatest EUV machines last year. That was a huge sign of confidence, and ASML's shares shot up 50% during the first half of 2024. Yet now facing a cash-crunch, Intel is delaying its new $30 billion Germany fab and is pushing out many of its previously-expected orders. That caused ASML to pull back on its fiscal year forecast and to suffer the wrath of a displeased and suddenly-very-grumpy market. With ASML regain the confidence of investors? Will Intel be an opportunity or a liability going forward? 7investing CEO Simon Erickson shares his thoughts in today's podcast. Would you like to see all of 7investing's stock market recommendations and monthly Best Buys? Learn more about how you can take our service for a 7-day free trial at 7investing.com/subscribe.

Lululemon (Nasdaq: LULU) has expanded from being a niche yoga retailer to an international fitness super-brand. New CEO Calvin McDonald has tripled its sales in five years and maintained its industry-leading 20% operating margin. Yet recently, perhaps due to concerns of a slowdown in consumer spending or of rising competition, the stock has been selling for a dirt-cheap valuation. Now priced at just 15x its trailing cash flow, it could an inexpensive opportunity for opportunistic investors to consider. Would you like to see our official Conviction Rating on Lululemon - meaning whether we think the stock is a "Strong Buy", "Buy", or "Hold"? See all of 7investing's recommendations, conviction ratings, and premium coverage by getting started FOR FREE today at ⁠7investing.com/subscribe⁠. Disclaimer: The 7investing podcast should not be considered personalized financial advise. Its host and guests may have positions in the stocks that are mentioned.

Our newest stock recommendation is now live! On the 1st of each month, 7investing issues its newest official recommendation. This is the one stock it feels most confident in adding to its scorecard (which we also track in real-time at 7investing.com/recommendations). What led us to recommend this Large Cap, Moderate Risk, Retail company this month? In today's episode, Simon describes 5 specific metrics that investors should consider when selecting stocks -- especially now that the Fed's cutting rates and we're in a more growth-friendly environment.

Booking Holdings (Nasdaq: BKNG) is one of the most efficient publicly-traded companies in the world, converting 50% of its 2024 revenue into cold, hard cash flow. Furthermore, it's using those operating cash flows in shareholder-friendly ways, such as repurchase large amounts of its stock and a newly-initiated dividend. 7investing CEO Simon Erickson takes a look at the company's second quarter results and discuss several initiatives that could be even better news for investors going forward. To sign up free for 7investing and see our most recent five Best Buys for September, visit 7investing.com/subscribe

7investing's Watch List of New Ideas introduces stocks that we've never formally recommended yet are worth considering as future scorecard additions. You can think of this as our pipeline of new investment opportunities. This month, 7investing CEO Simon Erickson is adding two new two European companies: BE Semiconductor (OTC: BESIY) and Novo Nordisk (NYSE: NVO). He describes why Besi's advanced packaging leadership makes it a natural winner from innovative new chip designs, and why Novo Nordisk is still in the earliest innings of introducing Ozempic as a treatment for obesity. 7investing makes its formal recommendations available through its Premium Membership. To see all of our stock market recommendations through a 100% free 7 day trial, join today at 7investing.com/subscribe.

Fertility benefits company Progyny's (Nasdaq: PGNY) stock is selling off 33% in today's trading session after announced it's losing its largest customer who accounted for 13% of the previous year's revenue. This customer was unnamed, but it's most likely Amazon. Even though Progyny has historically had nearly 100% client retention and receives excellent net promoter scores, this could be a red flag for investors. 7investing CEO Simon Erickson shares his thoughts about the company's previous struggles, the Alabama Supreme Court's recent ruling about IVF embryos, and how investors should think about Progyny's stock going forward.

Upstart Holdings (Nasdaq: UPST) has been one of the investing world's most volatile stocks. Since peaking at $400 per share in late 2021, its stock has fallen more than 90% and sits at just $35 today. Many believe this roller coaster ride has followed the American macroeconomy. The Zero Interest Rate policy directly following COVID was replaced by the fastest rise in interest rates the United States had ever seen in 2022. Yet Upstart might be seeing signs of life. It issued optimistic revenue guidance for the upcoming Q3 and Q4. Not coincidently, this aligns with the Fed suggesting that a rate cut is most definitely on the table. But investors aren't out of the woods just yet. In today's episode, 7investing CEO Simon Erickson describes the fundamental challenges Upstart still faces and why it doesn't have the most shareholder-friendly leadership team. See more of our coverage on Upstart and 200 other publicly-traded companies at 7investing.com!

Sometimes in investing, it's important to change your mind. Such is the case for Celsius Holdings (Nasdaq: CELH). This energy drink company represented one of our highest-conviction ideas in August. Yet further diligence revealed multiple red flags, which 7investing CEO Simon Erickson considers to be deal-breakers for long-term investors. In today's podcast episode, he describes several of those warnings signs and why he's turned from bullish to bearish about Celsius' future opportunity. Note: This podcast mentions 54% ownership for the DeSantis family, which is an incorrect number. Due to overlap between the beneficial ownership of three family trust funds, the actual family ownership stake is closer to 23%. To learn more about our long-term investing approach and to see all of our official stock market recommendations, visit 7investing.com.

Wolfspeed (NYSE: WOLF) is one of Wall Street's ultimate battleground stocks. As the world's largest provider of silicon carbide, it supplies one of the most necessary materials for next-generation Electric Vehicles. Based on the size of its potential market and the long-term supply agreements with large automakers, its stock appears to be extremely undervalued. Yet Wolfspeed is also facing some serious headwinds, specifically in government-supported financing to construct its fabs and lagging demand for EVs from consumers. It's fallen short of its explicitly-stated guidance, which has hurt its credibility with investors. So is Wolfspeed's stock a howling buy or a whimpering sell? In today's episode, 7investing Simon Erickson describes several of the opportunities and challenges that Wolfspeed faces. He discusses several financial and operational updates, the crucial difference between "design-ins" and "design-wins", and what investors should be watching most closely. 7investing issues Conviction Ratings for all of the stocks in our coverage universe. Ranging from "Strong Buy" to "Sell" and all points in between, these represent how confident we are about investing in a particular stock right now. To see our current Conviction Rating for Wolfspeed (which might actually surprise you), sign up for our premium membership at ⁠7investing.com/subscribe⁠. Use promo code "september" at checkout to waive our signup fee and to get your first week entirely free!

Tesla always gives investors plenty to talk about! In today's show, 7investing CEO Simon Erickson describes 3 key takeaways from the company's second quarter report: - The all-time high in regulatory credits, driven by attractive financing rates and political uncertainty - The Energy business recognizing an all-time high in revenue and growing 100% in year-over-year comparisons - A production and deliveries update on the Model S, X, and Cybertruck. Overall, Simon believes Tesla's stock is only worth $104 per share "as a car company" but is worth up to $650 per share "as an AI company". https://7investing.com/articles/tesla-the-ai-company-is-worth-645-per-share-heres-what-makes-the-stock-a-buy-today/ Join our free email list to have our investing insights delivered to your inbox every week: 7investing.com/email

The "organ transplant as a service" market is taking the medical world by storm. How long can the accelerated growth rates continue? TransMedics (Nasdaq: TMDX) is a unique company you might have never heard of. But it's playing an important role in saving the lives of thousands of Americans every year. As the creator of its patented Organ Care System (OCS), it is the only FDA-approved technology to transport lungs, hearts, and livers in the United States. When a registered donor is recently deceased, TransMedics' OCS keeps their organs functional long enough to be transplanted into another patient who is badly in need. The transplant must happen as quickly and as efficiently as possible, since this is a matter of life and death. In today's episode, 7investing CEO Simon Erickson describes this fast-growing new market and why it's eagerly being embraced by organ transplant centers. He also highlights two key risks that investors should consider when sizing up TMDX as a long-term opportunity.

United Therapeutics (Nasdaq: UTHR) is a very smart, very innovative, and very profitable company. First it treated an untreatable disease. Now it's disrupting the entire organ transplant industry. In today's show, 7investing CEO Simon Erickson introduces United Therapeutics, describing why the company was created and its five commercially-approved drugs. He also explains how its four synthetic organ programs could disrupt the entire organ transplant market. See why United Therapeutics is a stock that should be on your radar. To join our free email list, visit 7investing.com/email.